Autolus Therapeutics appoints Dolski as CFO, Hersberger, Neville as SVPs

Autolus Therapeutics announced the appointment of Robert Dolski as Chief Financial Officer, CFO, effective August 7, 2023. Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as Chief Financial Officer at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. in 2022. Dolski will succeed Dr. Lucinda Crabtree, who, as previously announced, will be leaving Autolus in August. Dr. Veronica Hersberger was appointed as Senior Vice President, SVP Medical Affairs in Q2 2023 and has started to build up this critical function as the Company prepares obe-cel for launch. Hersberger joined Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer. Additionally, Miranda Neville has been promoted to Senior Vice President, Project Management, effective immediately. Neville leads the obe-cel program and has served in various roles at Autolus, most recently as Vice President, Head of Program and Portfolio Management.